Guggenheim Cuts Janux Therapeutics (NASDAQ:JANX) Price Target to $68.00

Janux Therapeutics (NASDAQ:JANX) had its target price decreased by Guggenheim from $72.00 to $68.00 in a research note issued to investors on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

JANX has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Thursday, January 22nd. HC Wainwright dropped their target price on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Barclays decreased their price target on shares of Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. Clear Str lowered shares of Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Finally, Bank of America cut their price objective on shares of Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $56.91.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $13.61 on Friday. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $35.34. The stock has a market capitalization of $827.90 million, a P/E ratio of -7.44 and a beta of 2.88. The company’s 50-day moving average is $13.73 and its 200 day moving average is $20.68.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.14. The company had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $0.08 million. Research analysts anticipate that Janux Therapeutics will post -1.38 earnings per share for the current year.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, CEO David Alan Campbell sold 8,072 shares of Janux Therapeutics stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $110,828.56. Following the completion of the transaction, the chief executive officer directly owned 284,982 shares of the company’s stock, valued at approximately $3,912,802.86. The trade was a 2.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Zachariah Mciver sold 2,714 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $37,263.22. Following the sale, the insider owned 23,286 shares in the company, valued at approximately $319,716.78. The trade was a 10.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 19,033 shares of company stock worth $261,323 in the last 90 days. Insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Janux Therapeutics during the fourth quarter valued at $34,000. Osaic Holdings Inc. lifted its stake in Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after acquiring an additional 3,037 shares during the period. Virtus Investment Advisers LLC boosted its holdings in shares of Janux Therapeutics by 37.9% during the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock valued at $85,000 after acquiring an additional 1,011 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares during the last quarter. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Janux Therapeutics by 25.6% in the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after acquiring an additional 820 shares during the period. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.